Role of NKp46⁺ natural killer cells in house dust mite-driven asthma

Eline Haspeslagh¹,2,†, Mary J van Helden¹,3,†, Kim Deswarte¹,3, Sofie De Prijck¹,2, Justine van Moorleghem¹,3, Louis Boon⁴, Hamida Hammad¹,3, Eric Vivier⁵,6 & Bart N Lambrecht¹,3,†,*

Abstract

House dust mite (HDM)-allergic asthma is driven by T helper 2 (Th2) lymphocytes, but also innate immune cells control key aspects of the disease. The precise function of innate natural killer (NK) cells during the initiation and propagation of asthma has been very confusing, in part because different, not entirely specific, strategies were used to target these cells. We show that HDM inhalation rapidly led to the accumulation of NK cells in the lung-draining lymph nodes and of activated CD69⁺ NK cells in the bronchoalveolar lumen. However, genetically engineered Ncr1-DTA or Ncr1-DTR mice that constitutively or temporarily lack NK cells, still developed all key features of acute or chronic HDM-driven asthma, such as bronchial hyperreactivity, Th2 cytokine production, eosinophilia, mucus overproduction, and Th2-dependent immunoglobulin serum titers. The same results were obtained by administration of conventional NK1.1 or asialo-GM1 NK cell-depleting antibodies, antibody-mediated blocking of the NKG2D receptor, or genetic NKG2D deficiency. Thus, although NK cells accumulate in allergen-challenged lungs, our findings comprehensively demonstrate that these cells are not required for HDM-driven asthma in the mouse.

Keywords allergic asthma; house dust mite; NK cells; NKG2D; NKp46

Introduction

Asthma is a major and ever-increasing health problem that currently affects 300 million people worldwide (Lambrecht & Hammad, 2017). Allergic asthma is a prototype of type 2 immunity, orchestrated by an aberrant adaptive CD4⁺ T helper 2 (Th2) cell immune response to airborne allergens such as house dust mite (HDM). Th2 cells produce the cytokines IL-4, IL-5, IL-9, and IL-13, which induce immunoglobulin E (IgE) production by B cells, eosinophil infiltration of the airways, basophil and mast cell activation, and goblet cell hyperplasia and increased mucus production (Lambrecht & Hammad, 2014). The excessive inflammatory response causes bronchial hyperreactivity (BHR) and creates breathing difficulties. Although Th2 cells have historically been regarded as central mediators, several innate immune cells are also critically important in orchestrating various aspects of the allergic inflammatory response in mouse models (Akbari et al, 2003; Sokol et al, 2008; Hammad et al, 2009, 2010; Nussbaum et al, 2013; Plantinga et al, 2013; Halim et al, 2014; Schuijs et al, 2015).

Conventional natural killer (NK) cells are key components of innate immunity, best known for their anti-viral and anti-tumor activity. Moreover, NK cells are increasingly appreciated to play a regulatory role in the immune system, being capable of influencing DC functions (Degli-Esposti & Smyth, 2005; Walzer et al, 2005; Moretta et al, 2006), shaping CD8⁺ T cell memory responses (Soderquest et al, 2011; Crouse et al, 2014; Xu et al, 2014), and promoting CD4⁺ Th1 cell polarization (Martin-Fontera et al, 2004; Morandi et al, 2006; Lu et al, 2007). Under certain conditions, NK cells can even secrete Th2 cytokines, and thereby might promote or enhance type 2 immunity (Warren et al, 1995; Walker et al, 1998; Cooper et al, 2011).

NK cells are ubiquitously present in human and mouse lungs, where they comprise 10–15% of resident lymphocytes (Gregoire et al, 2007; Marquardt et al, 2017). Therefore, many studies have aimed at elucidating their role in allergic asthma. Initial studies have used NK1.1 or asialo-GM1 (ASGM1) depleting antibodies (Korsgren et al, 1999; Ple et al, 2010), or mice genetically deficient for the activating receptor NKp46 (Ghadially et al, 2013) or NKG2D (Farhadi et al, 2014). These studies showed that NK cells were crucial and non-redundant for asthma development induced by ovalbumin...
results of NKp46+ NK cells (Narni-Mancinelli et al., 2011). Although NK cells were activated in the bronchoalveolar lumen (BAL) of mice exposed to HDM, constitutive or temporary genetic depletion of NK cells did not reduce or enhance HDM-induced asthma features. This was confirmed in a more chronic asthma model and using another allergen. In our hands, also NKG2D-deficient mice developed normal HDM-induced eosinophilia. Taken together, our findings challenge earlier findings and show that NK cells play a minor role in the development of HDM-induced allergic asthma.

Results

HDM allergen activates NK cells in selected compartments

We first analyzed the impact of HDM exposure on NK cell numbers and activation in the lung interstitium, bronchoalveolar lumen accessible by lavage (BAL), and lung-draining mediastinal lymph nodes (MLNs). C57Bl/6 mice received an intratracheal (i.t.) instillation of a high dose of crude HDM extract, known to induce an innate immune response (Hammad et al., 2010), and NK cell responses were assessed over time (Fig 1A). In naïve mice, very few NK cells were located in BAL and MLNs (Fig 1B–D). From day 0.5 after HDM exposure, NK cells were easily detectable in both organs and numbers peaked at day 1.5, followed by a rapid decline. The expression of the activation marker CD69 on BAL, but not MLN, NK cells increased over time, suggesting an enhanced activation state (Fig 1F and G). In lung tissue from which circulating blood cells were flushed out, NK cell numbers were substantial in naïve mice (Fig 1B and E), consistent with earlier reports (Gregoire et al., 2007), and were not significantly influenced by HDM instillation. Lung NK cells did, however, temporarily gain some CD69 expression (Fig 1H). Thus, HDM instillation resulted in a temporary infiltration and activation of NK cells in various anatomical regions of the pulmonary immune system, including the inductive MLN site.

Absence of NKp46+ cells does not affect allergic asthma induced by several models

Several studies have been performed to address the role of NK cells in allergic asthma, using various markers to target or deplete NK cells (Korsgren et al., 1999; Ple et al., 2010; Ghadially et al., 2013; Farhadi et al., 2014). Some of these markers are also expressed by subsets of T cells in various inflammatory conditions (Slifka et al., 2000). Since activated CD4+ T cells are key players in allergic asthma, we determined the specificity of expression of NKp46, NKG2D, ASGM1, and NK1.1 on NK cells, NK1.1+ natural killer T (NKT) cells, and naïve and memory conventional CD4+ T cells in the lungs of naïve and asthmatic mice (Fig 2A and B). NKp46 was expressed on all NK cells, and a minor subset of NK1.1+ NKT cells, as previously reported (Walzer et al., 2007; Yu et al., 2011), whereas expression on naïve or memory T cells was absent in both groups of mice (Fig 2C). NK1.1, NKG2D, and ASGM1 were all highly expressed on NK cells, and particularly NK1.1 and NKG2D were also highly expressed on most NK1.1+ NKT cells. Thus, to deplete NK cells, NKp46 was first chosen based on its robust expression on all NK cells and limited expression on other cell types relevant to asthma.

Rosa-flox-stop-flox-diphtheria toxin A (RosaDTA/DTA) mice were crossed to mice that express Cre recombinase driven by the NKp46 promoter (Ncr1Cre/Cre) (Narni-Mancinelli et al., 2011; Deauvieau et al., 2016). ROSA/DTA/+/Ncr1Cre/+ mice, called NKp46-DTA hereafter, were confirmed to lack NKp46+ NK1.1+ CD3- cells in all investigated organs (Fig EV1A). These cells include bone fide NK cells, but also subsets of innate lymphoid cells (ILCs) type 1 (ILC1s) and ILC3s (Cella et al., 2009; Luci et al., 2009; Sanos et al., 2009; Cortez & Colonna, 2016). NKp46-DTA mice, and their littermate controls (Rosa+/+/Ncr1Cre/++), were i.t. sensitized to HDM and subsequently challenged with intranasal (i.n.) HDM inoculations on five repetitive days (Fig 3A). NKp46-DTA mice lacked NK cells in BAL (Fig 3B). HDM-sensitized, but not mock-sensitized, littermate mice exhibited strong bronchial hyperreactivity (BHR) in response to increasing doses of methacholine, and this response was also seen in NKp46-DTA mice (Fig 3C). In both littermate control and NKp46-DTA mice, HDM sensitization induced peribronchial and perivascular influx of immune cells in the lungs (Fig 3D), increased mucus production (Fig 3D), and eosinophil, B cell, and T cell infiltration in the BAL (Fig 3E), hallmarkst of type 2 immunity. Moreover, serum levels of Th2-associated HDM-specific immunoglobulins E (IgE) and IgG1 were not affected by NKp46+ cell absence (Fig 3F). The induction of eosinophilia and goblet cell metaplasia depends on IL-5 and IL-13, respectively. We therefore measured the presence of these key Th2 cytokines in total lung tissue, and their production by HDM-restimulated MLN cells. The levels of these and other cytokines (IL-10, IL-17, IFN-γ) were comparable between NKp46-DTA and littermate mice (Fig 3G and H).

Additionally, the response of NKp46-DTA mice was assessed in a more chronic HDM-driven model, adapted from Johnson et al. (2004) and Gregory et al. (2009), in which the mice were administered 25 µg HDM i.n. three times a week, for 3 weeks (Fig 4A and B). Again, the absence of NKp46+ cells did not significantly influence cardinal features of HDM-driven asthma (Fig 4C–E), although there was a trend toward lower HDM-specific IgG1 serum levels in NKp46-DTA mice. These findings contrast with earlier studies in OVA/alum-based allergic asthma models (Korsgren et al., 1999; Ple et al., 2010; Ghadially et al., 2013). To exclude allergen-dependency, littermate and NKp46-DTA mice were subjected to an OVA/alum-based allergic asthma model (Fig 4F and G). Again, we found that inflammatory cell infiltration in BAL upon OVA/alum-induced
Cardinal features of HDM-induced allergic asthma are not displayed in OVA.

Taken together, NKp46-DTA and littermate control mice displayed a very similar Th2-mediated asthmatic response to HDM (Fig 4H). Taken together, NKp46-DTA and littermate control mice displayed a very similar Th2-mediated asthmatic response to HDM (Fig 4H). Taken together, NKp46-DTA and littermate control mice displayed a very similar Th2-mediated asthmatic response to HDM (Fig 4H).

NKp46-DTA and littermate control mice displayed a very similar Th2-mediated asthmatic response to HDM (Fig 4H).

A Eight-week-old female C57Bl/6j mice were administered 100 μg HDM intratracheally. BAL, MLNs, and lung tissue were harvested on indicated time points for analysis by flow cytometry.

B NK cell infiltration in BAL, MLN single-cell suspensions, and homogenized lung tissue, pre-gated on live CD45+ single cells. One representative plot is shown for each condition, and percentage of NK cells (live, CD45+CD3/19-Nkp46+) of live CD45+ cells is indicated.

C-E Quantification of NK cell infiltration in BAL (C), MLN cell suspensions (D), and homogenized lung tissue (E).

F-H Mean fluorescence intensity (MFI) of activation marker CD69 on NK cells.

Data information: Data were analyzed with an unpaired Kruskal–Wallis test without multiple comparison correction, and individual data points are shown ± SEM. N = 5 mice for D0 and 4 for other time points. Results are representative of at least two independently performed experiments. **P < 0.01, ***P < 0.001 compared to day 0. $P < 0.05; $$P < 0.01; $$$P < 0.001 compared to day 0.5. All exact P-values are presented in Table EV1.

Cardinal features of HDM-induced allergic asthma are not influenced by NKp46+ cell absence during the sensitization or challenge phase only

In NKp46-DTA mice, ablation of NKp46+ NK cells occurs early during their maturation in the bone marrow (Narni-Mancinelli et al., 2011), raising the possibility of functional replacement of NK cells by other immune cell types during immune development. Moreover, previous studies have suggested that NK cells can fulfill opposing roles during asthma, depending on the models used (Korsgren et al., 1999; Ple et al., 2010; Ghadially et al., 2013; Farhadi et al., 2014; Ferrini et al., 2016; Simons et al., 2017; Wan Jiacheng Bi et al., 2017). We therefore considered the possibility that NK cells might have contrasting roles in the sensitization and challenge phase of the HDM-induced asthma model, which might be obscured in animals constitutively lacking NK cells. The influence of these two hypotheses was investigated by crossing Ncr1Cre/Cre+ mice to ROSA-stop-flox-stop-diphtheria toxin receptor (ROSA-DTR/DTR) mice (Narni-Mancinelli et al., 2011), generating a model of inducible and temporary NK cell depletion. DT injection efficiently depleted pulmonary NK cells in NKp46-DTA/DTR mice (Narni-Mancinelli et al., 2011), generating a model of inducible and temporary NK cell depletion. DT injection efficiently depleted pulmonary NK cells in NKp46-DTA/DTR mice (Narni-Mancinelli et al., 2011), generating a model of inducible and temporary NK cell depletion. DT injection efficiently depleted pulmonary NK cells in NKp46-DTA/DTR mice (Narni-Mancinelli et al., 2011), generating a model of inducible and temporary NK cell depletion. DT injection efficiently depleted pulmonary NK cells in NKp46-DTA/DTR mice (Narni-Mancinelli et al., 2011), generating a model of inducible and temporary NK cell depletion. DT injection efficiently depleted pulmonary NK cells in NKp46-DTA/DTR mice.
To investigate the role of NKp46+ cells during the allergic sensitization phase, NKp46-DTR mice and littermate controls were treated with DT before HDM sensitization, or NKp46-DTR mice were mock-treated with PBS, as an additional control (Fig 5A). NK cell depletion was confirmed non-invasively on blood samples (Fig 5C). NK cells were then allowed to reconstitute, and the mice were challenged with HDM 1 month after sensitization. All three groups of HDM-sensitized and HDM-challenged mice showed similar eosinophil infiltration (Fig 5G), cytokine production by HDM-restimulated MLN cells (Fig 5I), or HDM-specific IgE and IgG1 production (Fig 5J). Finally, NKp46-DTR mice were treated with DT or PBS both before HDM sensitization and before HDM challenges, and here again, BAL immune cell infiltration was similar in the two groups of HDM-sensitized and -challenged mice (Fig EV2A and B).

Figure 2. NK cell marker expression on pulmonary T, NKT, and NK cells remains unchanged in response to HDM-mediated allergic asthma.

A C57Bl/6 mice were sensitized intratracheally on day 0 with 1 μg HDM or PBS, followed by five consecutive intranasal challenges with 10 μg HDM or PBS 7 days later. Lungs were harvested and homogenized 4 days after the last challenge. B Gating strategy for identification of NK cells, NKp46+ NKT cells, and naïve (CD44−) and memory (CD44+) CD4+ T cells. C Representative histogram of NKp46, NK1.1, NKG2D, and asialo-GM1 expression on cell populations gated as in (B). Data are representative of two experiments with each two to three mice per group. FMO = Fluorescence minus one.

Figure 3. Absence of NKp46+ cells does not reduce nor exacerbate hallmarks of HDM-induced allergic asthma.

A On indicated time points, mice deficient of NKp46+ cells (NKp46-DTA, Ncr1<sup>Cre<sup>−/−</sup> ROSA<sup>DTA<sup>+</sup></sub></sub></sup>) and littermate controls (Ncr1<sup>Cre<sup>−/−</sup> ROSA<sup>DTA<sup>−/−</sup></sub></sub></sup>) were sensitized intratracheally with 1 μg HDM, or mock-sensitized with PBS, followed by five consecutive intranasal challenges with 10 μg HDM. 3–4 days later, bronchial hyperreactivity (BHR) was measured (C) or organs were harvested for analysis (B, D–G). Alternatively, lung tissue was harvested 3 h after the 4th challenge on day 10 (H). B NK cell (live, TCRβ<sup>−</sup> NK1.1<sup>+</sup> CD122<sup>+</sup>) numbers in BAL, assessed by flow cytometry. n = 7 (a, b) or 6 (c, d). C Airways resistance in response to increasing doses of methacholine (Mch). Data are pooled from two independent experiments, with total n = 7 (a), 14 (b), 7 (c) and 15 (d). *P = 0.0348, **P = 0.0058 for dose 400 mg/ml Mch compared to mock-sensitized control group (d to c and b to a, respectively). D Detection of mucus production by periodic acid-Schiff (PAS) staining on OCT-inflated lung cryosections. E Infiltration of eosinophils, neutrophils, B cells, and T cells to BAL, assessed by flow cytometry. Data are pooled from four independent experiments with total n = 17 (a), 28 (b), 19 (c), and 26 (d). F HDM-specific immunoglobulin serum levels, detected by ELISA. Data are pooled from three independent experiments with total n = 13 (a), 21 (b), 17 (c), and 20 (d). G MLN single-cell suspensions were restimulated with 15 μg/ml HDM for 3 days, and cytokine production was measured by ELISA. Data are representative of four independent experiments. n = 7 (a, b) or 6 (c, d). H Snap-frozen lung tissue was homogenized and analyzed for cytokine levels by ELISA, and for total protein content by NanoOrange technology. Results are depicted as pg cytokine/mg total protein. n = 5 (a, c) or 6 (b, d).

Data information: All data were analyzed with an unpaired Kruskal–Wallis test without multiple comparison correction and are shown as means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Exact P-values are presented in Table EV1.
Targeting NK cells with other (depletion) techniques does not affect HDM-induced allergic asthma

To facilitate a careful comparison with earlier studies, which utilized NK cell-depleting antibodies, we treated C57Bl/6 wild-type mice with anti-NK1.1 or anti-ASGM1 depleting antibodies, anti-NKG2D blocking antibodies, anti-β-galactosidase antibodies as a control, or anti-CD4 antibodies to deplete CD4⁺ T cells as an additional control (Fig 6A). Anti-NKG2D blocking antibody efficiently blocked NKG2D surface expression on splenic NK cells for at least
7 days (Fig EV3A and B). As depleted NK cells start to reconstitute after 4 days (Fig EV1A), all antibodies were administered every 3–4 days. NKG2D blocking or complete NK cell absence was again confirmed in the lungs at the time of sacrifice (Fig EV3C–F). Whereas CD4+ T cell depletion completely aborted influx of eosinophils in the BAL, administration of the other antibodies did not
Figure 5. Induced absence of NKp46⁺ cells during the sensitization or challenge phase of HDM-mediated allergic asthma does not influence asthma hallmarks.

(A–J) C57Bl/6 NKp46-DTR mice (Ncr1iCre⁺/ROSA DTR/+) or littermate controls (Ncr1iCre⁺/ROSA DTR/+) were sensitized intratracheally on day 0 with 1 µg HDM, or mock-sensitized with PBS. Four weeks (A) or 10 days (F) later, they were intranasally challenged on five consecutive days with 10 µg HDM. DT was injected at indicated time points, to deplete NKp46⁺ cells during the sensitization (A) or challenge (F) phase. Hallmarks of asthma were studied 3–4 days after the last challenge and shown in (B–E) and (G–J), respectively. (C, H) NK cell (live, TCR-β⁺ NK1.1⁺ CD122⁺) depletion was confirmed by flow cytometry on spleen cells. (B, G) Infiltration of eosinophils, neutrophils, B cells, and T cells in BAL, determined by flow cytometry. (D, I) MLN single-cell suspensions were restimulated with 15 µg/ml HDM for 3 days, and cytokine production was measured by ELISA. (E, J) HDM-specific immunoglobulin serum levels, detected by ELISA.

Data information: In (B, C, and E), n = 3 (c, e), 5 (f) or 6 (a, b, d), in (G, H, and J), n = 3 (e) or 4 (a, b, d, f), in (D and I), n = 5. BAL data are representative of two independently performed experiments. Data were analyzed with an unpaired Kruskal–Wallis test without multiple comparison correction, or with an unpaired Mann–Whitney test for (D and I), and are shown as means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001, $P < 0.05, $$$P < 0.01 for ≥ 2 control groups. All exact P-values are presented in Table EV1.
inhibit asthma hallmarks (Fig 6B–D). There was a trend for higher inflammatory cell influx in anti-ASGM1-treated animals, but this failed to reach statistical significance. Moreover, administration of anti-NK1.1 or anti-NKG2D also did not alter cardinal features of allergic asthma induced by the chronic HDM-based asthma model (Fig EV4A). The finding that administration of anti-NKG2D does not inhibit asthma hallmarks contrasts with earlier research that used mice genetically deficient for NKG2D (Farhadi et al., 2014). Accurate comparison of these results might be hampered by some undesirable side effects of antibody injection, such as nonspecific binding to Fc receptors, or surface receptor cross-linking followed by cell activation (Arase et al., 1997). To eliminate confusion from these side effects, Klrk1−/− mice and littermate controls were subjected to HDM-induced asthma (Fig 7A and B). This resulted in substantial and comparable HDM-specific IgE and IgG1 serum levels (Fig 7C), infiltration of eosinophils and other immune cells in the BAL (Fig 7D), and Th2 cytokine production by HDM-restimulated MLN cells (Fig 7E), in both NKG2D-deficient and littermate mice. Finally, genetic absence of NKG2D had no impact on BAL eosinophilia, Th2 cytokine production, or IgE and IgG1 serum levels in response to chronic HDM exposure (Fig EV5A–E).

**Discussion**

In this study, we comprehensively addressed the long-held hypothesis that NK cells play an important role in asthma. Using the most advanced method to genetically deplete Nkp46+ NK cells, we found no support for this hypothesis. Therefore, the claim of a true null hypothesis (NK cells do not play a critical role in asthma) was further
Published online: February 14, 2018

Eline Haspeslagh et al Natural killer cells in asthma

EMBO Molecular Medicine

Natural killer cells in asthma

Eline Haspeslagh et al

Eomes+ ILC1s in salivary glands, Eomes+ are dispensable for allergic asthma development in mice. Affecting asthma severity, we accept the null hypothesis that NK cells genetic NKG2D deficiency. As none of these intervention strategies the prototypic NK cell-activating NKG2D receptor using antibodies or we interfered with NK cell function rather than numbers by blocking depletion could not be the best option to reveal a role for NK cells, a model and a more chronic HDM-driven model. Finally, as cellular possibility that the role of NK cells during these phases might be asthma development (sensitization and challenge), eliminating the cells were also temporarily depleted during the separate phases of substantiated. NK cells were depleted during asthma development by the administration of conventional NK cell-depleting antibodies. NK cells were also temporarily depleted during the separate phases of asthma development (sensitization and challenge), eliminating the possibility that the role of NK cells during these phases might be opposite. To address any potential confounding bias due to the type animal model used, NK cells were depleted in an OVA/alum-based model and a more chronic HDM-driven model. Finally, as cellular depletion could not be the best option to reveal a role for NK cells, we interfered with NK cell function rather than numbers by blocking the prototypic NK cell-activating NKG2D receptor using antibodies or genetic NKG2D deficiency. As none of these intervention strategies affected asthma severity, we accept the null hypothesis that NK cells are dispensable for allergic asthma development in mice.

NKP46 is not entirely specific for NK cells and is also expressed on Eomes+ ILC1s in salivary glands, Eomes+ ILC1s in liver, skin, and peritoneum, and a subset of IL-22 producing ROR-γt+ ILC3s in the gut (Cella et al, 2009; Luci et al, 2009; Sanos et al, 2009; Cortez & Colonna, 2016). These populations are very rare in the lungs of naive mice, but the ILC1 population could potentially expand in inflamed tissues, as was shown for CD127+ ILC1-like cells in the spleens of chronically infected mice (Gasteiger et al, 2013). Additionally, NKP46 expression has been detected on a subset of non-CD1d restricted NK1.1+ NKT cells (Walzer et al, 2007; Yu et al, 2011) and a subset of γδTCR cells (Stewart et al, 2007). Our data suggest that all these cell (sub)populations are also dispensable for HDM-mediated asthma development.

Our findings are in marked contrast to earlier studies that have relied on targeting NK1.1, ASGM1, or NKG2D (Korsgren et al, 1999; Ple et al, 2010; Ghadially et al, 2013; Farhadi et al, 2014), none of which are unique for NK cells. NK1.1 is expressed on both NK and NKT cells, the latter possibly being able to modulate airway disease (Akbari et al, 2003; Berzins & Ritchie, 2014), and on some virus-specific CD4+ and CD8+ T cells (Sliška et al, 2000). ASGM1 has been detected on the majority of, but not all, murine NK cells, subsets of CD8+ T cells, basophils, and in some instances even on eosinophils or activated CD4+ T cells (Trambley et al, 1999; Sliška et al, 2000; Kataoka et al, 2004; Nishikado et al, 2011). We demonstrated NKG2D expression on NK cells, but also on activated CD4+ CD8+ T cells, albeit to a lesser extent. Moreover, NKG2D expression was detected on NKT cells,
γδT cells, and CD8+ T cells (Bauer, 1999; Jamieson et al., 2002). Nevertheless, in the two HDM models investigated here, depletion of NK1.1- or ASGM1-expressing cells did not blunt allergic inflammation, nor did the antibody-mediated blocking or genetic removal of the activating NKG2D receptor. Therefore, this study excludes differences in experimental techniques as an explanation for conflicting results and affirms our conclusions across several models of NK cell depletion or targeting.

Recently, interactions between NK cells and ILC2s have been demonstrated in HDM-induced allergic asthma, in which NK cells play an anti-inflammatory role (Ferrini et al., 2016; Simons et al., 2017). The absence of the eicosanoid CB2 or PGI3 receptor resulted in increased NK cell numbers in BAL, indirectly affecting ILC2s numbers and activity, and impediment of asthma development. By means of transfer studies, this was validated to be NK cell dependent. Notably, this anti-inflammatory role of NK cells was only observed in conditions where NK cells were strongly increased in number and possibly differentially activated. Indeed, WT mice, harboring physiological amounts of pulmonary NK cells, were perfectly able to develop inflammation upon HDM instillation, and anti-NK1.1 antibody treatment in these mice caused only a modest increase in total BAL cell numbers without influencing other investigated asthma hallmarks (Ferrini et al., 2016; Simons et al., 2017). Interestingly, the rare human NK cell deficiencies described in literature have not yet been associated with hypersensitivity reactions (Voss & Bryceson, 2017). Although the authors justly state that modulating NK cell function provides a promising therapeutic strategy, we here show that NK cells, when present in the physiological amounts and activation state imposed by HDM exposure, have negligible anti-inflammatory capacities.

Interestingly, none of the studies that demonstrated a pro-inflammatory function of NK cells mentioned the pathogen status of their animal facility. Our mouse studies were performed in specific pathogen free (SPF)-housed animals. Differences in housing conditions could potentially have an impact on gut microbiome diversity, which, in humans, has been shown to correlate with increased risk of atopic eczema or allergic asthma (Bisgaard et al., 2011; Abrahamsson et al., 2012). The risk of allergen sensitization might also directly be influenced by housing conditions; we previously showed that exposure to minute amounts of LPS or farm dust drastically blunted the allergic airway response, due to desensitization of the airway epithelium (Schuijs et al., 2015). Moreover, mice fed a high-fiber diet had a changed composition of gut and lung microbiome and were protected from allergic asthma development (Trompette et al., 2014). Therefore, the threshold for allergic sensitization could be increased in animal facilities in which animals have a different microbiome composition or are fed a different animal chow, or in which some pathogens are allowed to persist. This may then possibly necessitate additional innate signals, such as those delivered by NK cells, to develop a full-blown allergic response.

In summary, by using the newest genetic tools, we demonstrate that NK cells play a minor role in the establishment of HDM-induced allergic asthma. In the future, we have to more comprehensively assess the impact of environmental conditions and microbiome on the function of NK cells in asthma. Only then, we will be able to model and grasp the full therapeutic potential of these cells in human asthma.

Materials and Methods

Mice

Ncr1<sup>iCre/iCre</sup> mice were previously described (Narni-Mancinelli et al., 2011). <sup>ROSA</sup><sup>DTR/DTA</sup>, <sup>ROSA</sup><sup>DTR/DTR</sup>, and <sup>Ktrk<sup>1−/−</sup></sup> (Guerra et al., 2008) mice were obtained from The Jackson Laboratory. C57Bl/6J wild-type mice were obtained from Janvier. All mice were on a C57Bl/6 genetic background and 6–10 weeks old. As differences in male and female mice were not observed, both sexes were used and the mice were first age- and sex-matched, then randomly assigned per group and per experiment, without specific randomization procedure. Mice were housed and bred at the specific pathogen free (SPF) facility of VIB-University of Ghent, in individually ventilated cages with a controlled day-night cycle and given food and water <i>ad libitum</i>. Experiments conform to the Belgian laws and regulations concerning the use of animals for research and were approved by the Animal Ethical Committees of the University of Ghent and the Center of Inflammation Research.

Models of allergic asthma

NK cell kinetics following HDM exposure were investigated by i.t. instilling mice with 100 μg HDM. Acute HDM-induced allergic inflammation was established by i.t. sensitization with 1 μg HDM extract (Greer Laboratories), or with PBS as a control (day 0), followed by five consecutive i.n. challenges with 10 μg HDM (days 7–11). Asthma features were analyzed 3 or 4 days later. In the chronic HDM-induced asthma model adapted from (Johnson et al., 2004; Gregory et al., 2009), mice were instilled i.n. with 25 μg HDM, or PBS as a control, three times a week for 3 weeks. Asthma features were determined 24 h after the last challenge. OVA-mediated asthma was induced by an i.p. injection of 10 μg purified OVA (Worthington) absorbed on 1 mg alum (day 0), a boost i.p. injection of 10 μg purified OVA (day 7), and subsequent i.n. challenges on days 17–19 with 20 μg OVA. Asthma features were determined 24 h after the last challenge. All i.t. and i.n. treatments were given in 80 and 40 μl PBS, respectively, and under light isoflurane anesthesia.

<i>In vivo</i> ablation of cells or blocking of NKG2D

To deplete NKp46<sup>+</sup> cells in <sup>ROSA</sup><sup>DTR/DTA</sup> <sup>Ncr1<i>+</i>iCre</sup> mice, 200 mg DT (Sigma) was injected intravenously at indicated time points. For antibody-mediated depletion or blocking studies, mice were i.p. administered 200 μg of antibodies, diluted in PBS, every 3–4 days, starting at day −1. Anti-NKG2D (CX5), anti-CD4 (GK1.5), anti-NK1.1 (PK136), and control anti-β-galactosidase (GL113) antibodies were produced by Bioceres. Anti-ASGM1 was purchased from Wako and 50 μl of reconstituted (in 1 ml dH<sub>2</sub>O) antibodies were administered, diluted in PBS.

Effector cytokine production

Dissected MLNs were pressed through a 100-μM cell sieve. The acquired single-cell suspensions were seeded (2 × 10<sup>6</sup> cells/ml) in 96-well plates in RPMI-1640 medium supplemented with 5% fetal
calf serum (Bodino), 0.1% β-mercaptoethanol, glutamax (Gibco) and gentamycin (Gibco), and restimulated with 15 µg/ml HM for 3 days. Snap-frozen total lungs were homogenized in a tissue Lyser II device (Qiagen) for 4 min at 20 Hz, in 20% glycerol in dH2O with 40 mM Tris–HCl, 275 mM NaCl, and an EasyPack complete ULTRA-tablet mini (Roche). 2% Iqepal CA-630 (US biologicals) was added, and homogenates were rotated for 30 min and then centrifuged. MLN culture and homogenized lung tissue supernatants were analyzed for cytokine levels by ELISA (Ready-set-go kits from eBioscience), and for total protein concentration with NanoOrange technology (Thermo Fisher, Invitrogen).

Immunoglobulin production

Mice were bled under terminal anesthesia, and serum was collected by centrifugal phase separation to determine IgE and IgG1 levels by ELISA (BD Biosciences). For HDM-specific IgG1, ELISA plates were coated with 100 µg/ml HM (Greer Laboratories); For HDM-specific IgE, the supplemented detection antibody was interchanged for biotin-labeled HDM (100 µg/ml), diluted in PBS + 10% FCS.

Flow cytometry

Bronchoalveolar lumen fluid was obtained by flushing the lungs with EDTA-containing PBS (0.5 mM) via a cannula inserted in the trachea. Spleens and MLNs were dissected and pressed through a 100-µm cell sieve. Bones were crushed with mortar and pestle in RPMI-1640 medium and filtered through a 70-µm cell sieve. Whole lungs were isolated in RPMI-1640 medium supplemented with DNAse I recombinant Grade I (10 U/ml) and Liberase TM (20 µg/ml), both purchased from Roche. Lung tissue was dissociated using the GentleMACS (Miltenyi Biotec) lung programs 1 and 2, with gentle shaking at 37°C for 30 min in between both steps. The reaction was stopped by adding excess PBS, and the obtained single-cell suspensions were filtered through a 100-µm sieve. Cell suspensions were treated with osmotic lysis buffer, stained with antibody cocktails in PBS for 30 min at 4°C, and subsequently washed in PBS supplemented with 2 mM EDTA, 0.5% BSA, and 0.01% sodium azide. Unspecific antibody binding was prevented by adding 2.4G2 (antibody to the Fcγ receptor II/III) during the staining. Dead cells were excluded by adding fixable viability dye conjugated to eFluor506 (eBioscience). A fixed amount of counting beads (123count ebeads, eBioscience) were coated with 100 µg/ml HM (Greer Laboratories) for determination of absolute cell numbers. Antibodies used for flow cytometry are summarized inTable EV2. Samples were acquired on an LSRFortessa (4 laser, BD Biosciences) and analyzed using Flowjo Software (Tree Star, Inc.). In BAL, eosinophils were gated as CD11c- CD3/19- Ly6G- CD11bhi (eBioscience) and analyzed using Flowjo Software (Tree Star, Inc.).

Mucus production

Lungs were inflated with 1 ml PBS/OCT (1:1) solution (Tissue-Tek), snap-frozen in liquid nitrogen, and cryosectioned (7 µm) using the HM560 microtome (Thermo Scientific) for PAS staining. Pictures were obtained with AnalySIS getIT (Olympus Soft Imaging Solutions).

The paper explained

Problem

Allergic asthma is a major health problem that currently affects 300 million people worldwide. A thorough understanding of the underlying pathogenesis is key to the development of curing therapies. Asthma is mainly driven by T helper 2 lymphocytes, but several cells of the innate immune system also control key aspects of the disease. The role of conventional natural killer (NK) cells, however, remains elusive. Although NK cells have been proposed as a suitable target for asthma therapy, murine studies on their function in asthma are conflicting, in part because different, not entirely specific, tools have been employed to deplete NK cells or target their function.

Results

In mice that were given inhaled house dust mite, a clinically relevant allergen, NK cells migrated to the lungs and lung-draining lymph nodes. However, Ncr1- DTA mice, which are genetically engineered to lack all NK cells in the most specific way to date, still robustly developed asthma symptoms upon acute or chronic house dust mite exposure. Temporary depletion of NK cells during separate phases of asthma development in Ncr1- DTR mice also had no impact on the inflammatory phenotype. The results were additionally confirmed by injecting conventional NK cell-depleting antibodies. Finally, antibody-mediated blocking of the NK cell-activating NKG2D receptor, or genetic NKG2D deficiency, did not alter asthma severity.

Impact

This study challenges earlier findings and demonstrates that NK cells are not necessary for house dust mite-dependent asthma development. It thus suggests that NK cells may not be the most robust and all-encompassing therapeutic target to tackle allergic asthma. Alternatively, it suggests that we may need a more comprehensive assessment of the influence of environmental and microbial conditions on the precise role of NK cells in asthma.

BHR determination

Mice were anesthetized with urethane, paralyzed with D-tubocurarine, tracheotomized, and intubated with a 28-G catheter, followed by mechanical ventilation in a Flexivant apparatus (SCIREQ). Respiratory frequency was set at 150 breaths/min with a tidal volume of 10 ml/kg, and a positive-end expiratory pressure of 3 cm H2O was applied. Increasing concentrations of methacholine were nebulized (0–400 mg/ml); baseline resistance was restored in between the doses. A standardized inhalation maneuver was given every 10 s for 2 min per dose, and dynamic resistance and compliance were recorded.

Statistics

Sample sizes (n) represent the number of independent biological replicates and were chosen according to previous experience with the used experimental asthma models. Investigators were not blinded during the experiments and/or analyses. The differences between two, or more, groups were calculated with the Mann–Whitney U-test for unpaired data, or the Kruskal–Wallis test for unpaired data, respectively, without multiple comparison correction (GraphPad Prism version 7.0; GraphPad, San Diego, CA). These non-parametric statistical tests were chosen because data were not
normally distributed, and/or because normal distribution of the data sets could not be assumed due to too small sample sizes and/or unequal variances between experimental groups. Data are shown as means ± SEM, or as individual data points, where n < 5. N-values and statistical tests used are mentioned in the figure legends; all relevant P-values < 0.15 are depicted in the figures. All exact P-values are represented in Table EV1.

Expanded View for this article is available online.

Acknowledgements
This work was supported by the Flanders Research Foundation (Grant Number FWO13/ASP138 to E.H.), and The Lung Foundation Netherlands (Grant Number 3.2.11.090FE to M.J.v.H.). The B.N.L. laboratory is supported by an ERC consolidator grant (61004510VW), several FWO project grants, a Ghent University grant (GOA 01G02817), and an FWO Excellence of Science (EOS) award (Grant Number 0G02318N). The E.V. laboratory is supported by ERC, ANR, Innate-Pharma, MSDAvenir, la Ligue Nationale contre le Cancer (Equipe labellisée ‘La Ligue’) and by institutional grants from INSERM, CNRS, Aux-Marseille University and Marseille-Immunopole to the CIML. The funding sources had no role in the study design, collection, and interpretation of the data or writing of the manuscript.

Author contributions

Conflict of interest
Disclosure of potential conflict of interest: Prof. Dr. Eric Vivier is co-founder, scientific advisor, and shareholder of Innate-Pharma. The other authors declare that they have no conflict of interest.

References

Natural killer cells in asthma  Eline Haspeslagh et al
License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.